The ATM facility, coming just 14 days after a $6.5M-share underwritten offering, signals aggressive capital raising by a pre-revenue biotech. Monitor daily trading volumes for ATM sales — Stifel will sell into the market at prevailing prices, creating persistent overhang. Watch for any clinical catalyst (GH001 data) that could offset dilution pressure.
Price Chart
Executive Summary
GH Research PLC filed a 424B5 prospectus supplement to register an at-the-market (ATM) equity offering of up to $200 million of ordinary shares through Stifel as sales agent. The company is a clinical-stage biopharmaceutical developing mebufotenin therapies for treatment-resistant depression. The ATM facility adds potential dilution of up to ~9.3 million shares at the current $21.54 price, representing ~15% of shares outstanding post-April 2026 offering. Proceeds are earmarked for R&D, clinical development, and general corporate purposes.
Key Facts
- ATM equity offering of up to $200,000,000 of ordinary shares via Stifel as sales agent
- Up to 9,285,051 shares issuable at $21.54/share (May 12, 2026 closing price)
- Agent commission of up to 3.0% of gross sales price
- Estimated total offering expenses of ~$385,000 excluding commissions
- As of March 31, 2026: 62,052,506 shares outstanding; pro forma net tangible book value $4.24/share
- After full ATM sale: as-adjusted net tangible book value $6.41/share; immediate dilution of $15.13/share for new investors
- 6,527,779 shares issued in an underwritten offering on April 30, 2026 (just 14 days prior)
- Company was a PFIC for 2025 and expects to be a PFIC in 2026
- No revenue reported; clinical-stage biopharmaceutical with no approved products
Financial Impact
Up to $200M gross proceeds; immediate dilution of $15.13/share (70% of offering price) for new investors; ~15% share count increase at full utilization
Risk Factors
- Substantial dilution to existing shareholders from ATM sales
- No guarantee of any sales under the ATM; proceeds uncertain
- Clinical-stage company with no approved products or revenue
- PFIC status creates adverse tax consequences for U.S. holders
- Broad discretion in use of proceeds may lead to inefficient capital allocation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001140361-26-021169 |
| Document: 0001140361-26-021169-index-headers.html | 0001140361-26-021169 |
| Document: 0001140361-26-021169-index.html | 0001140361-26-021169 |
| Document: 0001140361-26-021169.txt | 0001140361-26-021169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers